Keytruda (pembrolizumab) is the first FDA approved immunotherapy drug that blocks the protein - receptor (programmed cell death - PD-1) allowing patients immune system to attack cancer.
Israel is one of the few countries allowed to use Keytruda not only for melanoma, but also as a new first-line treatment for lung cancer and for metastatic or recurrent small-cell neck or head carcinoma. Keytruda has been officially used in Israel since 2014 and has become a part of a "essential medicines package" in the following year.
The Israeli medical centers involved in the clinical trials of the drug detected improvement of treatment of melanoma without the side effects caused by traditional chemotherapy (like hair loss). The drugs also have shown promise as a “long-lasting” treatment for selected oncological diseases, but doctors continue to learn more as the drugs are used outside of clinical trials.
Tested at Sheba Medical Center, Keytruda deals with tumors using the body’s own immune system. An Israeli-tested drug was a key in helping former US president Jimmy Carter in his fight with life-threatening tumors after he was diagnosed with melanoma at the end of 2015.
The course of treatment for each patient is different. Israeli oncologists determine the number of procedures based on experience in chemotherapy and patient's general medical state.
Bookimed does not add extra charges for Immunotherapy with Keytruda (Pembolizumab) prices. The rates come from the clinics' official price lists. You pay directly at the clinic for your Immunotherapy with Keytruda (Pembolizumab) upon your arrival.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Immunotherapy with Keytruda (Pembolizumab) and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Immunotherapy with Keytruda (Pembolizumab) journey.
| The USA | Turkey | Mexico | |
| Immunotherapy with Keytruda (Pembolizumab) | from $21900 | from $7300 | from $8395 |
Prof. Peled is a leading specialist in lung cancer immunotherapy, with expertise in Internal Medicine, Pulmonology and Medical Oncology. He has received the ASCO Merit Award, and is the head of the Thoracic Cancer Unit at Davidoff Cancer Center and Head of the Research and Detection Unit for Thoracic malignancies at Sheba Medical Center. He is a member of the Thoracic Oncology Assembly of the European Respiratory Society and Chair of the Early Detection and Prevention Committee of the International Association for the Study of Lung Cancer.